Your Location：Home >Products >Custom peptide >247062-33-5
Product Details
Quality products make an important contribution to long-term revenue and profitability.
Abaloparatide is a synthetic peptide analog of the first 34 amino acids of the human parathyroid hormone-related peptide (PTHrP). It belongs to the parathyroid hormone-related protein analog class of medications and is used to treat osteoporosis, particularly in post-menopausal women. The medication shares 76% sequence homology with human PTHrP. Compared to other medications like human PTH (1–34) or teriparatide, abaloparatide has 42% homology, with 20 amino acids being exchanged.
The CAS number of Abaloparatide is 247062-33-5.
|
CAS Number |
247062-33-5 |
Synonyms for CID 145705876 247062-33-5:abaloparatide;BA058;tymlos
The chemical formula of Abaloparatide is C174H300N56O49 which containing 174 Carbon atoms,300 Hydrogen atoms,56 Nitrogen atoms and 49 Oxygen atoms,and the molecular weight of Abaloparatide is 3961.
Abaloparatide functions as an anabolic agent and interacts with the parathyroid hormone receptor 1 (PTHR1) on osteoblasts to induce bone formation. It is used in the management and treatment of osteoporosis, with the aim of increasing bone density. However, it's important to note that common side effects include hypercalciuria and dizziness. While abaloparatide shares similarities in its osteoanabolic effects with teriparatide, both preclinical and clinical studies highlight differences in their impact on bone health.
Relevant articles related to Abaloparatide:
|
Abaloparatide: A review of preclinical and clinical studies |
The first study of abaloparatide in healthy non-comorbid animals was published by Jolette et al. The study investigated the carcinogenic potential of daily treatment with abaloparatide (10, 25, or 50 μg/kg) over a two-year period using F344 rats. , European Journal of Pharmacology Volume 909, 15 October 2021, 174409 |
| Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis | Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis. , The Journal of Clinical Endocrinology & Metabolism, Volume 105, Issue 3, March 2020, Pages 938–943 |
Sichuan Jisheng BioPharmaceutical Co., Ltd. is a quality supplier of Abaloparatide. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Abaloparatide 247062-33-5.
CAS：79561-22-1
CAS：40077-57-4
CAS：N-Acetyl Selank Amidate
CAS：128270-60-0
